• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
RGS
Click for more information
0.00% 12.0¢

REGENEUS LTD - News & Media

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight

A regenerative medicine company, using stem cell and immuno-oncology technologies to develop a portfolio of cell-based therapies to address unmet medical needs in the human and animal health markets with a focus on osteoarthritis & other musculoskeletal disorders, oncology and dermatology diseases.
View the full Corporate Spotlight arrow Created with Sketch.

Regeneus achieves major milestones

No News & Media currently available.

Top Stories

Pro Medicus signs landmark $330M deal to roll out imaging platform in US hospitals

Pro Medicus Ltd is set to roll out a suite of diagnostic imaging products across the health care system run by Trinity Health
Chimeric clocks $4.17M R&D tax rebate from Canberra Chimeric Therapeutics (ASX:CHM) has confirmed its receipt of a $4.17M tax rebate from Canberra for R&D activities.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Australian Rare Earths bullish on early-stage uranium potential at Overland, SA Australian Rare Earths has asserted it's set to launch follow up drilling after aircore results show potential uranium downhole at Overland.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.